June 2020
Volume 61, Issue 7
ARVO Annual Meeting Abstract  |   June 2020
Mixed dry eye patients successfully treated by the innovative high-frequency electrotherapy device Rexon-Eye®
Author Affiliations & Notes
  • Alfredo Ruggeri
    Resono Ophthalmic, Sandrigo, Italy
  • Eleonora Fatigati
    Carones Vision, Milan, Italy
  • Luca Vigo
    Carones Vision, Milan, Italy
  • Footnotes
    Commercial Relationships   Alfredo Ruggeri, Resono Ophthalmic (I), Resono Ophthalmic (P); Eleonora Fatigati, None; Luca Vigo, Resono Ophthalmic (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 114. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alfredo Ruggeri, Eleonora Fatigati, Luca Vigo; Mixed dry eye patients successfully treated by the innovative high-frequency electrotherapy device Rexon-Eye®. Invest. Ophthalmol. Vis. Sci. 2020;61(7):114.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : We investigated the efficacy of an innovative treatment in a small cohort of nine patients affected by mixed dry eye disease (MDED), i.e., both aqueous deficient and evaporative type. The treatment consists in the administration of a specific low-power, high-frequency electric current using the Rexon-Eye® device.

Methods : Nine consecutive MDED patients were recruited and all treated. Therapy was administered with the Rexon-Eye® device (Resono Ophthalmic, Sandrigo, Italy, patented), which applies a low-power electric current with a specific spectrum of frequencies (4-64 MHz, Quantum Molecular Resonance, QMR®, patented). Patients were administered one 20 min treatment per week, for 4 weeks, and were examined at baseline and two month after the last treatment, by measuring: lipid layer thickness, tear meniscus, and non-invasive tear break-up time (NIBUT), all measured with IDRA (SBM Sistemi, Turin, Italy); Ocular Surface Disease Index (OSDI) score; tear osmolarity (TearLab, Escondido (CA), USA); ocular inflammation (InflammaDry; Quidel, San Diego (CA), USA).

Results : Results are reported in Table 1 and 2. The clinical endpoints improved significantly in most of the patients and no adverse events nor side effects were observed in any of them.

Conclusions : The innovative therapeutic device Rexon-Eye®, based on the QMR® patented electric stimulation, proved to be very effective in improving subjective and objective ocular parameters in most of the mixed dry eye patients of this study.

This is a 2020 ARVO Annual Meeting abstract.




This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.